Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tavo111
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : YuanBio Venture Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Details : The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform.
Product Name : Tavo111
Product Type : Antibody
Upfront Cash : Undisclosed
March 22, 2021
Lead Product(s) : Tavo111
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : YuanBio Venture Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Details : The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.
Product Name : YS-ON-001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 01, 2020